Arterial wall dosimetry for non-hodgkin lymphoma patients treated with radioimmunotherapy

Journal of Nuclear Medicine

Volumn 51, Issue 3, 2010, Pages 368-375

  Hobbs, Robert F ^a   Baechler, Sébastien ^b   Wahl, Richard L ^a   He, Bin ^a   Song, Hong ^a   Esaias, Caroline E ^a   Frey, Eric C ^a   Jacene, Heather ^a   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Lymphoma; Monte Carlo; Oncology; Radiobiology dosimetry; Radioimmunotherapy; Radionuclide therapy; SPECT CT; Toxicity

Indexed keywords

TOSITUMOMAB I 131; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY;

ARTERIAL WALL THICKNESS; ARTERIAL WALL TOXICITY; ARTERY DISEASE; ARTICLE; CASE REPORT; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; GEOMETRY; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; AGED; ARTERY; COMPUTER PROGRAM; FEMALE; KINETICS; MALE; METHODOLOGY; MIDDLE AGED; MONTE CARLO METHOD; RADIATION EXPOSURE; RADIOMETRY;

AGED; ANTIBODIES, MONOCLONAL; ARTERIES; FEMALE; HUMANS; KINETICS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MONTE CARLO METHOD; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; SOFTWARE;

EID: 77950365150     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.069575     Document Type: Article

References (40)

1. von der Weid NX. Adult life after surviving lymphoma in childhood. Support Care Cancer. 2008;16:339-345.
2. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2005;23:6508-6515. (Pubitemid 46190242)
3. Rademaker J, Schoder H, Ariaratnam NS, et al. Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR. 2008;191:32-37. (Pubitemid 351955179)
4. Scott AS, Parr LA, Johnstone PA. Risk of cerebrovascular events after neck and supraclavicular radiotherapy: a systematic review. Radiother Oncol. 2009;90:163-165.
5. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007;25:43-49. (Pubitemid 350003049)
6. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831-2837.
7. Izzedine H, Cluzel P, Deray G. Renal radiation-induced arterial stenosis. Kidney Int. 2007;71:1188.
8. Andersson A, Naslund U, Tavelin B, Enblad G, Gustavsson A, Malmer B. Longterm risk of cardiovascular disease in Hodgkin lymphoma survivors: retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124:1914-1917.
9. Patel DA, Kochanski J, Suen AW, Fajardo LF, Hancock SL, Knox SJ. Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Cancer. 2006;106:718-725. (Pubitemid 43157637)
10. Brosius FC III, Waller BF, Roberts WC. Radiation heart disease: analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70:519-530.
11. Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation. J Clin Oncol. 2006;24:5735-5741.
12. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl 1):99S-106S.
13. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224. (Pubitemid 23306322)
14. Hoving S, Heeneman S, Gijbels MJ, et al. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. Int J Radiat Oncol Biol Phys. 2008;71:848-857. (Pubitemid 351749524)
15. Pakala R, Leborgne L, Cheneau E, et al. Radiation-induced atherosclerotic plaque progression in a hypercholesterolemic rabbit: a prospective vulnerable plaque model? Cardiovasc Radiat Med. 2003;4:146-151.
16. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449. (Pubitemid 40175970)
17. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323. (Pubitemid 30159851)
18. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
19. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463. (Pubitemid 34525730)
20. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
21. 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose. J Nucl Med. 2008;49:837-844.
22. Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48:1008-1016. (Pubitemid 46909931)
23. 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison. J Nucl Med. 2009;50:1844-1847.
24. He B, Du Y, Song XY, Segars WP, Frey EC. A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT. Phys Med Biol. 2005;50:4169-4185. (Pubitemid 41225264)
25. Hudson HM, Larkin RS. Accelerated image-reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601-609.
26. 131I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005;46(suppl 1):128S-140S.
27. Ekström L, Firestone R. WWW Table of Radioactive Isotopes: Nuclide Search. Available at: http://ie.lbl.gov/toi/nucSearch.asp. Accessed February 1, 2010.
28. International Commission on Radiological Protection. Reference Man: Anatomical, Physiological, and Metabolic Characteristics. ICRP publication 23. Oxford, U.K.: Elsevier; 1975.
29. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm. 2004;19:363-370. (Pubitemid 38924502)
30. Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35:1123-1134. (Pubitemid 351322658)
31. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy. J Nucl Med. 2008;49:1884-1899.
32. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679-694.
33. Aref A, Mohammad R, Yudelev M, et al. Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma cell lines. Radiat Oncol Investig. 1999;7:158-162. (Pubitemid 29310098)
34. Brenner DJ, Miller RC, Hall EJ. The radiobiology of intravascular irradiation. Int J Radiat Oncol Biol Phys. 1996;36:805-810.
35. Brenner DJ, Hall EJ. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 1991;20:181-190.
36. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18:89-97.
37. Hobbs RF, Sgouros G. Calculation of the biological effective dose (BED) for piece-wise defined dose-rate fits. Med Phys. 2009;36:904-907.
38. Goyal S, Cohler A, Camporeale J, Narra V, Yue NJ. Intensity-modulated radiation therapy for orbital lymphoma. Radiat Med. 2008;26:573-581.
39. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
40. 131I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25:1396-1402.